- • Up to 20%-50%* off first purchase
- • Bulk quantities available
- • Citation Reward application
AAV ProDUCTS & SERVICE
AAV TECHNICAL RESOURCE
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
AAV8 variant (Y733F,Y447F) Rep-Cap plasmid (Pancreas and reina-validated serotype AAV-RC plasmid) (Amp and Kanamycin) (GeneMedi Owned)
GeneMedi's AAV8-2m Rep-Cap plasmid supplies the AAV2 Rep (replication) proteins and the AAV8-2m capsid protein.
You can produce AAV8-2m particle in 293T cell line in high titer using GeneMedi's AAV8-2m Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
The tissue tropism of AAV8 variant(Y733F,Y447F) vector has been validated in in Pancreas and retina,with potential applications in tissue-specific gene therapy and cancer therapy.
GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids.
Go to AAV
vector system
>>Product Description
| Cat.NO | Product Name | Organization Type | Price(In USD) | ||
|---|---|---|---|---|---|
| P-RC11 | AAV8-2m Rep-Cap Plasmid (Amp resistance) Size：5ug | Academic | 1719 | ||
| P-RC11 | AAV8-2m Rep-Cap Plasmid (Amp resistance) Size：5ug | Industry R&D (excluding CRO&CDMO&CXO) |
|||
| P-RC11 | AAV8-2m Rep-Cap Plasmid (Amp resistance) Size：5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
| P-RC11 | AAV8-2m Rep-Cap Plasmid (Amp resistance) Size：≥10mg |
All | |||
| P-RC11-Kan | AAV8-2m Rep-Cap Plasmid (Kan resistance) Size：≥10mg |
All | |||
| P-PK11 | AAV8-2m Vector
System (Amp resistance)
1. AAV8-2m Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug |
Academic | 3024 | ||
| P-PK11 | AAV8-2m Vector
System (Amp resistance)
1. AAV8-2m Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Industry R&D (excluding CRO&CDMO&CXO) |
|||
| P-PK11 | AAV8-2m Vector
System (Amp resistance)
1. AAV8-2m Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
| P-PK11 | AAV8-2m Vector
System (Amp resistance)
1. AAV8-2m Rep-Cap Plasmid, ≥10mg 2. AAV Helper Plasmid, ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01-Kan), ≥10mg |
All | |||
| P-PK11-Kan | AAV8-2m Vector
System(Kan resistance)
1. AAV8-2m Rep-Cap Plasmid(Kan resistance), ≥10mg 2. AAV Helper Plasmid(Kan resistance), ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), ≥10mg |
All | |||
|
GeneMedi offers both seed and amplification services for the Amp-resistant AAV Rep-Cap Plasmid. GeneMedi only offers amplification services and do not provide seed for the Kan-resistant AAV Rep-Cap Plasmid currently. |
|||||
| If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service. | |||||
|
Terms of sale: For Seed (5ug): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party. For plasmid production& amplification (≥10mg): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party. |
|||||
Citation
| Title | Publication | Date |
|---|---|---|
| Exosome-mediated miR-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration, and invasion through regulating ZEB1 | Molecular Cancer | 2023/7/17 |
| Skeletal muscle-derived extracellular vesicles transport glycolytic enzymes to mediate muscle-to-bone crosstalk | Cell Metabolism | 2023/11/7 |
| Anterior cingulate cortex dysfunction underlies social deficits in Shank3 mutant mice | Nature Neuroscience | 2019/7/22 |
| IRX2 regulates angiotensin II-induced cardiac fibrosis by transcriptionally activating EGR1 in male mice | Nature Communications | 2023/8/16 |
| Targeted Degradation of Signal Transduction and Activator of Transcription 3 by Chaperone-Mediated Autophagy Targeting Chimeric Nanoplatform | ACS Nano | 2023/12/29 |
| CircRNA-vgll3 promotes osteogenic differentiation of adipose-derived mesenchymal stem cells via modulating miRNA-dependent integrin α5 expression | Cell Death & Differentiation | 2020/8/19 |
| Functional reconstruction of injured corpus cavernosa using 3D-printed hydrogel scaffolds seeded with HIF-1α-expressing stem cells | NATURE COMMUNICATIONS | 2020/6/1 |
| Canonical transient receptor potential channel 1 aggravates myocardial ischemia-and-reperfusion injury by upregulating reactive oxygen species | Journal of Pharmaceutical Analysis | 2023/9/1 |
| Metformin accelerates bone fracture healing by promoting type H vessel formation through inhibition of YAP1/TAZ expression | Bone Research | 2023/8/16 |
| DUB1 suppresses Hippo signaling by modulating TAZ protein expression in gastric cancer | Journal of Experimental & Clinical Cancer Research | 2022/7/12 |
Validation data
Figure. Selected transduction results of AAV in vitro (in 293T cell line)
Virus and titer: AAV1/AAV6/AAV8/AAV-Rh10/AAV-DJ/AAV9-GFP, 1×1012 vg/ml
Cells: HEK-293T
MOI: MOI=1×104
Determine assay: 36 hours post infection, immunofluorescence microscopy
Associated products and services
| Products & Service | Products & Service Information |
|---|---|
| AAV Packaging service | Detail |
| Promise-ORF™ viral CDNA library | Detail |
| Plasmid DNA Rapid Preparation Service | Detail |
Facebook
LinkedIn
Twitter
